Navigation Links
Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
Date:11/17/2010

GENEVA and RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2010 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented an update to the World Health Organization (WHO) on the development of the company's lead antiviral compound, CMX001, at the 12th Meeting of the WHO Advisory Committee on Variola Virus Research in a presentation titled "Status of CMX001 for Smallpox and Other dsDNA Viruses."  CMX001 is being developed for dual-use as a medical countermeasure in the event of a smallpox release and as a broad-spectrum antiviral for the treatment of life-threatening viruses in immunocompromised transplant and cancer patients.

"Chimerix is passionate about the need to develop effective antiviral therapeutics to improve global health and protect against viral threats such as smallpox.  Therefore, we are pleased by the opportunity to provide an update to the World Health Organization on the significant progress being made in the development of CMX001 as a potential dual-use agent," commented Wendy Painter, M.D., M.P.H., Chief Medical Officer of Chimerix.  "In addition to proven efficacy in numerous animal studies against pox viruses, we are amassing a significant body of clinical data in critically-ill patients regarding CMX001's safety and antiviral activity against double-stranded DNA viruses."

CMX001 is currently in Phase 2 clinical trials for prophylaxis of human cytomegalovirus infection and under development using the FDA's "Animal Rule" for smallpox infection.  It has proven effective in reduction of morbidity and mortality in animal models of smallpox, even when treatment is initiated after the onset of lesions.

CMX001 has a number of advantages over other drugs in development for treatment of smallpox, including: broad-spectrum inhibition of double-stranded DNA (dsDNA) viruses that cause human disease; a high barrier to resistance; convenient oral administrati
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
2. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
3. Chimerix to Present at Upcoming Investor Conferences
4. Chimerix Initiates Phase 1 Study of CMX157
5. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
6. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
7. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
8. Chimerix Joins International Network of Organizations to Cure Malaria
9. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
10. Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany
11. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... EUGENE, Ore. -- Scientists, including University of Oregon ... to create scaffolds of self-assembling, synthetic proteins called ... processes. , The accomplishment -- detailed this week ... by the Proceedings of the National Academy ... an alternative design of the two-dimensional peptoid nanosheets ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Myriant ... the signage of a distribution agreement with Azelis ... now distributing Myriant’s bio-succinic acid in the Nordics, ... Ireland, targeting customers in the industrial and base ... powerhouse, Azelis offers a far-reaching chemical portfolio with ...
(Date:9/2/2014)... ROCKVILLE, Md. , Sept. 2, 2014 /PRNewswire/ ... of novel anti-infective biologic and drug candidates targeting ... announced today positive results from its final preclinical ... Drug Administration (FDA) guidance, this bridging study was ... product candidate designed to prevent the devastating effects ...
(Date:9/2/2014)... The inventors of tinAway, a novel treatment ... seeking support for development costs through a crowdfunding campaign. ... ), was launched on September 1, 2014. , tinAway ... is based on ten years of neuroscience research. ... software engineers, Dr. Ian Dixon and Mr. Tony Burgess, ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... The Muscular Dystrophy Association announced today that it ... biotechnology company, to develop and test a "dissociative glucocorticoid" ... (DMD) . (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO ) ... Institutes of Health Therapeutics for Rare and Neglected Diseases ...
... May 3, 2012 ZyGEM Corp. Ltd., a developer ... DNA and other nucleic acids, today announced it has ... distribution of ZyGEM,s DNA and RNA extraction products in ... a leading provider of quantitative real-time PCR (qPCR) services ...
... SEATTLE, May 3, 2012 CMC Biologics, a leading ... technical excellence in process development and cGMP manufacture ... Manufacturing Company of the Year – Large Category.   The ... partnership with Impact Washington, brought together nearly 300 leaders ...
Cached Biology Technology:MDA Supports Development of 'Dissociative Glucocorticoid' for DMD 2MDA Supports Development of 'Dissociative Glucocorticoid' for DMD 3ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits 2ZyGEM Teams With TATAA Biocenter To Distribute Its Innovative Nucleic acid Extraction Kits 3CMC Biologics Honored as Finalist for Washington's Manufacturing Company of the Year Award 2
(Date:9/2/2014)... losing weight is enough to prevent Type 2 diabetes, don,t ... 2014 issue of The FASEB Journal , ... Type 2 diabetes. This study compared genetically identical twins-one heavier ... the circulating metabolites, including those related to Type 2 diabetes, ... These findings suggest that the onset of this type of ...
(Date:9/2/2014)... birds, also known as perching birds, that migrate by ... do in autumn to reach their destinations. This seasonal ... that only make short migratory flights, says researcher Cecilia ... Behavioral Ecology and Sociobiology . , Nilsson, ... a tracking radar to measure over three years the ...
(Date:9/2/2014)... the last decade in Taiyuan, China, have substantially improved ... greater than 50% reduction in costs associated with loss ... to researchers at the Columbia Center for Children,s Environmental ... the Shanxi Medical University, the Center of Diseases Control ... School of Public Health. , The study is the ...
Breaking Biology News(10 mins):What you eat and not just the number of calories, is a significant factor in diabetes risk 2Migrating birds sprint in spring, but take things easy in autumn 2Clean air halves health costs in Chinese city 2
... at least 20 percent of adults in the United ... that prevents bones from rubbing together. By studying the ... how the earliest stages of arthritis make the tissue ... running or jumping. The findings could help researchers ...
... ARBOR, Mich. For nearly two years, University of Michigan ... clinical trial of stem cell injections in patients with the ... ALS or Lou Gehrig,s disease. Now, a new ... way for U-M to become the second site in the ...
... sometimes called "hardening of the arteries" is ... countries. A cell-permeable peptide containing the NF-ĸB nuclear localization ... controlling the development of atherosclerotic disease. This study is ... American Journal of Pathology . Atherosclerosis is a ...
Cached Biology News:Hop, skip or jump? Study says no to all of the above 2Hop, skip or jump? Study says no to all of the above 3FDA approves Phase II of stem cell trial for ALS led by U-M's Dr. Eva Feldman 2Cell-permeable peptide shows promise for controlling cardiovascular disease 2
... The Fujifilm Life Science FLA-8000 Fluorescent Image ... in a single laser imaging system. This ... samples labeled with fluorescent dyes or radioisotopes ... most demanding laboratories. Speed, image quality and ...
...
...
... PC, is used to perform runs ... from the Experion automated electrophoresis system. ... and simulated gel views and summarizes ... a Results table. This software is ...
Biology Products: